Abstract Library

#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: MULLER N

Authors: Muller N, Zappa M, Hammel P, De Mestier L, Laurent L,

Keywords: portal hypertension,

#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Olivia H

Authors: Hentic O, Cros J, Rebours V, Zappa M, Muller N,

Keywords: dedifferentiation, new biopsy,

#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,

#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)

Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cros J

Authors: Cros J, Hentic O, Rebours V, Zappa M, Maire F,

Keywords: MGMT, pancreatic NET, temozolomide,

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,